RNAi

September 10, 2018 A Triumph of Perseverance Over Interference [Nature Biotechnology] The following Editorial appeared in Nature Biotechnology (36,775 2018) on September 6, 2018... "A triumph of perseverance over interference"... Read More ›
August 11, 2018 New Kind of Drug, Silencing Genes, Gets FDA Approval [Wall Street Journal] The following article appeared in The Wall Street Journal on August 10, 2018... "New Kind of Drug, Silencing Genes, Gets FDA Approval"... Read More ›
April 30, 2018 Hunting for Targets: Bringing RNAi to Humans Evolution is a powerful force, and Mother Nature is often a great source of inspiration for drug hunters like me. If you look at the history of successful... Read More ›
April 30, 2018 Building to Scale: Raising RNAi Therapeutics From Infancy When I joined Alnylam in 2004, one of our early challenges was figuring out how to manufacture and deliver RNAi therapeutics for our clinical trials. The... Read More ›
February 28, 2018 Harnessing the Power of RNAi™: Pushing Through the Challenges and Setbacks I am an organic chemist, and what keeps me going after 3 decades working in the field of oligonucleotides is transforming complex chemistry into medicines... Read More ›
February 28, 2018 RNAi Therapeutics: From Eureka! Moment to a Potential New Class of Medicines How far science and technology have come! At Alnylam, we believe we’re on the verge of a landmark moment in medicine and I can’t help but express my... Read More ›
Subscribe to RNAi

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site